Actinium PharmaceuticalsATNM
ATNM
About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Employees: 49
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,417% more call options, than puts
Call options by funds: $91K | Put options by funds: $6K
93% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 14
1.13% less ownership
Funds ownership: 27.2% [Q3] → 26.07% (-1.13%) [Q4]
4% less funds holding
Funds holding: 72 [Q3] → 69 (-3) [Q4]
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
36% less capital invested
Capital invested by funds: $15.9M [Q3] → $10.2M (-$5.68M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
188%
upside
Avg. target
$4
188%
upside
High target
$4
188%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 17% 1-year accuracy 73 / 418 met price target | 188%upside $4 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Based on 47 articles about ATNM published over the past 30 days
Neutral
Accesswire
8 hours ago
Levi & Korsinsky Reminds Actinium Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 27, 2025 - ATNM
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=140778&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
9 hours ago
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK , April 3, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Neutral
Accesswire
10 hours ago
Shareholders that Lost Money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=140750&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
11 hours ago
ROSEN, A LONGSTANDING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025.
Neutral
GlobeNewsWire
15 hours ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Neutral
Accesswire
15 hours ago
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=140644&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
16 hours ago
ATNM STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between March 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period").
Neutral
Accesswire
1 day ago
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=140564&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Business Wire
1 day ago
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK--(BUSINESS WIRE)---- $ATNM #ATNM--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE: ATNM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired.
Neutral
Accesswire
1 day ago
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) between October 31, 2022, and August 2, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Charts implemented using Lightweight Charts™